Company news

PDS Biotechnology Corporation news in 2022

PDS Biotechnology Corporation's news releases, calls and decks from 2022, newest first.

View company

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

December 27, 2022

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

December 14, 2022

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

November 13, 2022

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

November 6, 2022

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

October 30, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

October 16, 2022

PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022

October 11, 2022

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

October 10, 2022

PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 6, 2022

PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022

October 4, 2022

PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®

October 2, 2022

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2022

PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

September 20, 2022

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance

August 23, 2022

PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update

August 7, 2022

PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

August 3, 2022

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results

July 25, 2022

PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting

July 13, 2022

PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel

June 2, 2022

PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101

June 1, 2022

PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe

May 30, 2022

PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

May 25, 2022

PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022

May 25, 2022

PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development

May 17, 2022

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

May 10, 2022

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

April 27, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

April 26, 2022

PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

April 18, 2022

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

March 30, 2022

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

March 21, 2022

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

March 14, 2022

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

March 8, 2022

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

February 23, 2022

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

February 14, 2022

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

February 1, 2022

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

January 26, 2022

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

January 11, 2022

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

January 9, 2022

Calls in 2022

Decks in 2022